AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Melexis N.V.

Earnings Release Feb 3, 2021

3975_er_2021-02-03_94027f5d-ffca-44c6-9ed1-7327da066e9d.pdf

Earnings Release

Open in Viewer

Opens in native device viewer

Press release - Regulated Information

Melexis Q4 and FY 2020 results – Full year sales of 507.5 million EUR

Intermediate declaration by the Board of Directors

Ieper, Belgium – February 3rd , 2021, 07.00 hrs CET

CONFORM IFRS FY 2020 FY 2019 YOY growth
in k EUR (%)
Sales 507,517 486,862 4%
Gross result 197,988 196,234 1%
Gross Margin 39.0% 40.3%
EBIT 75,534 70,626 7%
EBIT in % 14.9% 14.5%
EBITDA 121,905 119,231 2%
EBITDA in % 24.0% 24.5%
Net result 69,299 60,255 15%
Net result per share (EPS) 1.72 1.49
CAPEX 24,835 26,632

Sales for the full year of 2020 were 507.5 million EUR, an increase of 4% compared to the previous year. The EUR/USD exchange rate evolution had a negative impact on sales of 1% compared to 2019.

The gross result was 198.0 million EUR or 39.0% of sales, an increase of 1% compared to 2019. R&D expenses were 15.3% of sales, G&A was at 6.1% of sales and Selling was at 2.7% of sales.

The operating result was 75.5 million EUR or 14.9% of sales, an increase of 7% compared to 70.6 million EUR in 2019.

The net result was 69.3 million EUR or 1.72 EUR per share, an increase of 15% compared to 60.3 million EUR or 1.49 EUR per share in 2019.

CONFORM IFRS Q4 2020 Q4 2019 YOY growth Q3 2020 SEQ growth
in k EUR (%) (%)
Sales 147,400 127,052 16% 121,568 21%
Gross result 58,293 50,424 16% 44,854 30%
Gross Margin 39.5% 39.7% 36.9%
EBIT 25,763 18,280 41% 15,687 64%
EBIT in % 17.5% 14.4% 12.9%
EBITDA 37,038 30,773 20% 26,759 38%
EBITDA in % 25.1% 24.2% 22.0%
Net result 24,012 15,371 56% 14,905 61%
Net result per share (EPS) 0.59 0.38 0.37
CAPEX 8,131 6,081 5,249

Sales for the fourth quarter of 2020 were 147.4 million EUR, an increase of 16% compared to the same quarter of the previous year and an increase of 21% compared to the previous quarter.

The EUR/USD exchange rate evolution had a negative impact on sales of 3% compared to the same quarter of last year and a negative impact of 1% compared to the previous quarter.

The gross result was 58.3 million EUR or 39.5% of sales, an increase of 16% compared to the same quarter of last year and an increase of 30% compared to the previous quarter.

R&D expenses were 13.7% of sales, G&A was at 5.9% of sales and Selling was at 2.5% of sales. The operating result was 25.8 million EUR or 17.5% of sales, an increase of 41% compared to the same quarter of last year and an increase of 64% compared to the previous quarter.

The net result was 24.0 million EUR or 0.59 EUR per share, an increase of 56% compared to 15.4 million EUR or 0.38 EUR per share in the fourth quarter of 2019 and an increase of 61% compared to the previous quarter.

Dividend

The Board of Directors approved on January 29th, 2021 to propose to the Annual Shareholders meeting to pay out over the result of 2020 a total dividend of 2.20 EUR gross per share. This amount contains an interim dividend of 1.30 EUR per share which was paid in October 2020 and a final dividend of 0.90 EUR per share which will be payable after approval of the Annual Shareholders meeting.

The Melexis shares will start trading ex coupon on May 12, 2021 (opening of the market). The record date is May 13, 2021 (closing of the market) and the dividend will be payable as from May 14, 2021.

Outlook

Melexis expects sales in the first quarter of 2021 to be in the range of 155 to 160 million euro.

For the full year 2021, Melexis expects sales growth between 15% and 20%, with a gross profit margin around 41% and an operating margin around 19% at the midpoint of the sales guidance, all taking into account a EUR/USD exchange rate of 1.21.

Business comment – Françoise Chombar, CEO:

"After two difficult years in which we faced severe global trade tensions and an unprecedented pandemic, the end of 2020 marked a turning point for Melexis. Despite the numerous challenges that COVID-19 posed, out of adversity came opportunity: next to catering to our valued automotive customers as always, Melexis also tapped into adjacent applications that gained momentum with the COVID-19 outbreak. As a result, we concluded the year with a 4% year-over-year sales growth.

During the fourth quarter, we launched no less than 8 new products, half of which are specifically conceived for adjacent markets such as 2-/3-wheelers, home appliances and products forindustrial use. Newly launched automotive products include current sensors, a smart tire sensor and a novel motor driver for mechatronic applications, all of which serve the future car, carbon free and intelligent. Based on 2020 data, we can now

state that on average, every new car worldwide carries 13 Melexis chips on board from 11 the year before. All this makes me very proud and excited for the future.

Sales to automotive customers represented 88% of total sales, both in the fourth quarter and in the full year 2020. The portion of standard product (ASSPs) sales represented 70% of total sales in the fourth quarter and 69% in the full year 2020.

At the start of 2021, we are witnessing exceptionally strong order behavior, driven by steep restocking and revived end market demand. This condensed ordering pattern is now causing supply chain and delivery disruptions in parts of the automotive industry, the bullwhip effect in action at warp speed. Having intentionally kept its inventories at a higher than usual level in the past year, Melexis had a head start to cope with this elevated demand.

The 2021 full year sales guidance we provide is built on the one hand on meeting the strong order behavior we see today for the first half of the year, while also remaining cautious about the evolution of end market demand in the second half of the year."

The statutory auditor PwC Bedrijfsrevisoren BV has confirmed that the audit, which is substantially complete, has not to date revealed any material misstatement in the draft consolidated accounts, and that the accounting data reported in the press release is consistent, in all material respects, with the draft accounts from which it has been derived.

Financial Calendar

  • Publication Q1 Results 2021: April 28, 2021 (at 7 hrs CET)
  • Annual Shareholders Meeting: May 11, 2021
  • Dividend pay date: May 14, 2021 (ex coupon on May 12, 2021)
  • Analyst Meeting: June 1st, 2021
  • Publication Q2 Results 2021: July 28, 2021 (at 7 hrs CET)
  • Publication Q3 Results 2021: October 27, 2021 (at 7 hrs CET)
  • Publication FY 2021 Results: February 2, 2022 (at 7 hrs CET)

The company's results will be discussed in a conference call and an audiocast on Wednesday, February 3rd, 2021 at 10:30 hrs CET.

To register for the conference call (possibility to ask questions)

The conference call will be in English. You have to register for this conference call in advance. You can register by clicking here and filling out the requested information. After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes, all participants must register individually if they wish to join the call.

To register for the audiocast (no possibility to ask questions)

To register for the audiocast, click here.

For more information: Investor Relations Phone: +32 13 67 07 79 Email: [email protected]

About Melexis

Combining a passion for technology with truly inspired engineering, Melexis designs, develops and delivers innovative micro-electronic solutions that enable designers to turn ideas into applications that support the best imaginable future. The company's advanced mixed-signal semiconductor sensor and actuator components address the challenges of integrating sensing, driving and communication into next-generation products and systems that improve safety, raise efficiency, support sustainability and enhance comfort. Melexis is headquartered in Belgium and employs over 1500 people in 19 locations worldwide. The company is publicly traded on Euronext Brussels (MELE). For more information, visit www.melexis.com

Disclaimer

Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forwardlooking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.

Consolidated Income Statement

CONFORM IFRS Quarter ended
31/12/2020
Quarter ended
31/12/2019
Year ended
31/12/2020
Year ended
31/12/2019
in k EUR audited audited
Sales 147,400 127,052 507,517 486,862
Cost of sales -89,107 -76,628 -309,529 -290,628
Gross result 58,293 50,424 197,988 196,234
R&D -20,247 -20,497 -77,691 -79,558
G&A -8,644 -7,624 -30,930 -30,600
Selling -3,638 -4,023 -13,834 -15,450
Other operating result
Operating result (EBIT) 25,763 18,280 75,534 70,626
Financial result 1,222 -401 379 -1,378
Result before taxes 26,985 17,879 75,913 69,248
Income taxes -2,973 -2,507 -6,613 -8,993
Net result 24,012 15,371 69,299 60,255
Net result per share in EUR 0.59 0.38 1.72 1.49

Consolidated Statement of Financial Position

CONFORM IFRS Year ended
31/12/2020
Year ended
31/12/2019
in k EUR audited audited
Current Assets :
Cash and cash equivalents 58,883 38,772
Current investments 245 78
A/R Trade 65,099 58,310
A/R from related parties 372 136
Advance related parties
Assets for current tax 4,695 1,745
Assets held for sale
Other current assets 10,637 9,781
Inventories 123,457 128,505
Total current assets 263,389 237,328
Non-current assets :
Costs of incorporation
Property, plant and equipment 129,949 143,608
Leased assets 2,731 4,813
Financial assets 0 0
Intangible fixed assets 4,650 5,209
A/R directors
Other non-current assets 4,203 3
Deferred tax assets 28,490 27,649
Total non current assets 170,023 181,282
Total assets 433,412 418,610
CONFORM IFRS Year ended Year ended
31/12/2020 31/12/2019
in k EUR audited audited
Liabilities and shareholders Equity
Current liabilities :
Bank loans and overdrafts
Derivative financial instruments
Current portion of LT debt
Lease liabilities 1,633 1,825
A/P trade 18,328 16,139
Affiliated companies 15,759 15,733
Accrued taxes 473 3,251
Accrued expenses and payroll 11,882 10,643
Other current liabilities 3,433 4,305
Deferred income 2,799 2,280
Total current liabilities 54,307 54,176
Non current liabilities :
LT debt less current portion 62,000 62,000
Lease liabilities 2,122 3,027
Deferred tax liabilities 207 337
Other non-current liabilities
Total non current liabilities 64,329 65,364
Shareholders' equity :
Shareholders' capital 565 565
Share premium
Treasury shares -3,818 -3,818
Revaluation reserve Hedge
Revaluation reserve Fair value
Legal reserve 57 57
Retained earnings 254,786 246,601
Current period's profit 69,299 60,255
Cumulative translation adjustment -6,113 -4,590
Equity attributable to company owners 314,776 299,070
Non controlling interests 0 0
Total shareholders equity 314,776 299,070
Total liabilities, shareholders' equity 433,412 418,610
and minority interests

Consolidated Statements of Cash Flow

CONFORM IFRS Quarter ended Quarter ended Year ended Year ended
31/12/2020 31/12/2019 31/12/2020 31/12/2019
(in k EUR) audited audited
Cash flow from operating activities
Net income 24,012 15,371 69,299 60,255
Adjustments for :
Operating activities 18,125 11,685 47,626 59,459
Deferred taxes -32 -2,367 -841 -2,655
Capital grants 364 531 942 1,099
Depreciation and amortisation 10,773 11,904 44,453 46,760
Depreciation leased assets 502 589 1,918 1,845
Accrued income tax 8,934 1,369 4,550 10,374
Unrealized exchange results -2,841 9 -2,213 -604
Financial result 425 -350 -1,184 2,640
Operating profit before working capital changes 42,137 27,056 116,925 119,714
A/R, Trade -1,770 11,363 -6,974 16,938
A/R, affiliates -273 -61 -237 25
Other current assets -2,907 1,739 -4,756 -2,687
Other non current assets -4,200 -4,200 1
Inventories 6,893 -2,218 -210 -14,303
A/P 3,199 2,465 2,237 -4,678
A/P affiliates 7,050 2,815 26 1,765
Accrued expenses -1,280 -1,788 1,239 141
Other current liabilities -1,646 -334 -870 1,537
Other non current liabilities 275 -49 389 -721
Interest paid
Income tax paid
-112
-9,561
-240
-3,515
-482
-7,327
-523
-22,808
Cash flow from operating activities 37,806 37,233 95,761 94,401
0 0
Cash flow from investing activities
Acquisition of subsidiary, net of cash acquired
Financial fixed assets
Purchase of PPE and intangible assets (netted) -8,131 -6,081 -24,835 -26,632
Interest received 3 18 56 90
Investments/proceeds/ from current investments -35 -79 -167 22
Investments/proceeds/ from non current investments
(incl. financial instruments)
Cash provided from investing activities -8,164 -6,142 -24,946 -26,519
Cash flows from financing activities
Payment to acquire own shares
Proceeds/Repayment of long-and short-term debt 21 94 26,927
Proceeds/Repayment of bank loans and overdrafts
Repayment leasings 481 -584 -934 -1,805
Proceeds from (repayment of) related party financing
Impact of exchange results on financing items 2,003 228 2,272 -661
Dividend payment -52,070 -52,070 -52,070 -88,118
Capital Decrease
Non controlling interests 0 -10 -10
Cash provided from financing activities -49,565 -52,436 -50,639 -63,668
CTA -26 -31 -65 37
Increase/decrease in cash and cash equivalents -19,948 -21,377 20,112 4,250
Cash at beginning of the period 78,831 60,150 38,772 34,522
Cash at the end of the period 58,883 38,772 58,883 38,772

Sales per Geography

Q4 2020 Q4 2019 FY 2020 FY 2019
APAC
Asia Pacific
54% 51% 55% 47%
EMEA
Europe - Middle-East - Africa
36% 37% 34% 39%
NALA
North America - Latin America
10% 12% 11% 14%
TOTAL 100% 100% 100% 100%

Talk to a Data Expert

Have a question? We'll get back to you promptly.